EGFR and head and neck cancer: Contemporarily, there is increasing evidence supporting the concomitant use of cetuximab, a monoclonal antibody against the epidermal growth factor receptor (EGFR), in addition to high-dose radiotherapy in primary treatment concepts of head and neck cancer [1].